United Health Products Retains Legal Counsel Ruskin Moscou Faltischek P.C. to Assist in Strategic Review

Henderson, Nevada – November 2, 2018  United Health Products, Inc. (OTCQB: UEEC), manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it has retained Ruskin Moscou Faltischek P.C. to assist it and Société Général in its previously announced Review of Strategic Alternatives.

In connection with the FDA PMA Class III approval process for HemoStyp, UHP has been contacted by a number of medical technology companies that are active in the surgical equipment and hemostatic products sectors, and who have expressed an interest in the Company's products and business strategy. In response to these inbound contacts, and to maximize shareholder value, the Company's board of directors has determined to conduct a review of strategic alternatives, which include a potential sale of the Company, joint venture or other commercial partnership, or a standalone growth plan.

About Ruskin Moscou Faltischek P.C

For 50 years, Ruskin Moscou Faltischek P.C., headquartered in Uniondale, New York has built a reputation as one of the region's leading providers of innovative legal services. Its attorneys are practical, experienced advocates who measure their success by their clients' success. Cornerstone groups in all major practice areas of the law are represented at the firm, including corporate and securities, financial services, commercial litigation, intellectual property, health care, real estate, employment, not-for-profit, cybersecurity and data privacy, energy, and trusts and estates. Clients include large and mid-sized corporations, privately held businesses, institutions and individuals. 

About United Health Products Inc.

United Health Products Inc. (UHP) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose. HemoStyp is an all natural product designed to absorb exudate/drainage from wounds to help control bleeding. UHP is focused on identifying new markets and applications for its products and expanding its current markets. UHP currently sells a suite of hemostatic products to the dental, veterinary and retail markets.
For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Company Contact:
United Health Products, Inc.
877-358-3444

IR Contact:
PAN Consultants Ltd.
Philippe Niemetz 
212-344-6464

United Health Products United Health Engages Société Générale to Undertake Strategic Review’

Henderson, Nevada – October 25, 2018  United Health Products, Inc. (OTCQB: UEEC), manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today announced the following corporate developments:

Review of Strategic Alternatives

In connection with the FDA PMA Class III approval process for HemoStyp, UHP has been contacted by several medical technology companies that are active in the surgical equipment and hemostatic products sectors, and who have expressed an interest in the Company's products and business strategy. In response to these inbound contacts, and to maximize shareholder value, the Company's board of directors has determined to conduct a review of strategic alternatives, which include a potential sale of the Company, joint venture or other commercial partnership, or a standalone growth plan. To assist in this review, the Company has retained Société Générale to serve as financial advisor to the Company. The Company notes that there is no assurance this review will result in any transaction, and it will not reveal details of developments related to its review unless and until the board has approved a specific transaction or otherwise determined that further disclosure is appropriate. 

About Société Générale Corporate & Investment Banking

Société Générale Corporate & Investment Banking (SG CIB) is a full-service investment banking firm offering tailor-made solutions to corporates, financial institutions and the public sector in over 40 countries. SG CIB's U.S. advisory operations are based in New York and provide strategic advice and transaction execution expertise across the technology, healthcare, consumer, industrial and natural resources sectors. 

About United Health Products Inc.

United Health Products Inc. (UHP) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose. HemoStyp is an all natural product designed to absorb exudate/drainage from wounds to help control bleeding. UHP is focused on identifying new markets and applications for its products and expanding its current markets. UHP currently sells a suite of hemostatic products to the dental, veterinary and retail markets.
For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Company Contact:
United Health Products, Inc.
877-358-3444

IR Contact:
PAN Consultants Ltd.
Philippe Niemetz 
212-344-6464 

  


United Health Products’ HemoStyp® to Begin Human Trials

Henderson, Nevada – August  8, 2018  United Health Products, Inc. (OTCQB: UEEC), ), manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that its protocol submission for human testing has been reviewed by the Food and Drug Administration (FDA). This FDA review has been provided to the Institutional Review Board (IRB) for protocol and hospital site approval. United Health Products expects the human trial study to commence mid-August.

The IRB is a committee that is independent of the FDA, and that is formally designated to approve, monitor, and review biomedical and behavioral research involving humans. The purpose of the IRB is to assure that appropriate steps are taken to protect the rights and welfare of humans participating as subjects in a research study.

UHP’s human trial protocol calls for the application of HemoStyp in abdominal, cardiovascular thoracic and vascular surgical procedures to control bleeding sites. Prior to finalizing its human trial protocol, UHP submitted a Q-Sub –a request for FDA review—to the FDA, in conjunction with its previously filed Class III PMA submission application. 

The HemoStyp human trial is a prospective, non-inferiority, multi-center, randomized, open-label trial to observe HemoStyp in the management of bleeding during surgery; and, to assess the efficacy and safety of HemoStyp as an adjunct for management of secondary hemostasis in an operative setting. UHP’s independently developed protocol has established endpoints for bleeding control and stopping. The trial will operate under the Non-Significant Risk (NSR) category of Investigational Device Exemption (IDE). NSR devices do not pose a significant risk to the human subjects. Submissions for NSR device investigations are made directly to the IRB of each participating institution.   

“We expect that this human trial will be the last step to clear in obtaining FDA PMA Class III approval for HemoStyp, “said, Louis Schiliro, COO, UHP. “We have recruited a team of leading surgeons to conduct the study, and our lead investigator has successfully conducted over 20 FDA trials as Primary Investigator. These are indeed exciting times for UHP, as we aim to complete the final regulatory stage and prepare for entry into the $ 2.9 billion domestic hemostasis surgical market.”

About United Health Products Inc.

United Health Products Inc. (UHP) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose. HemoStyp is an all natural product designed to absorb exudate/drainage from wounds to help control bleeding. UHP is focused on identifying new markets and applications for its products and expanding its current markets. UHP currently sells a suite of hemostatic products to the dental, veterinary and retail markets.
For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Company Contact:
United Health Products, Inc.
877-358-3444

IR Contact:
PAN Consultants Ltd.
Philippe Niemetz 
212-344-6464 

  


United Health Products to Offer Retail Sales of HemoStyp® Products on Walmart.com and Jet.com

Henderson, Nevada – July 09, 2018 – United Health Products, Inc. (OTCQB: UEEC),manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it has been accepted as a Walmart.com and Jet.com supplier, and will offer three HemoStyp wound care products for online retail sale. HemoStrip® Hemostatic Bandages, BooBoo Strip Hemostatic Bandages, and a multipack of HemoStyp® Trauma Gauze will be available for purchase on Walmart.com and Jet.com in the near future. 

About United Health Products Inc. 
United Health Products Inc. (UHP) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose. HemoStyp is an all natural product designed to absorb exudate/drainage from wounds to help control bleeding. UHP is focused on identifying new markets and applications for its products and expanding its current markets. UHP currently sells a suite of hemostatic products to the dental, veterinary and retail markets.
For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Company Contact:
United Health Products, Inc.
877-358-3444

IR Contact:
PAN Consultants Ltd.
Philippe Niemetz 
212-344-6464 

  


United Health Products to Offer Retail Sales of HemoStyp® Products on Walmart.com and Jet.com

Henderson, Nevada – July 09, 2018 – United Health Products, Inc. (OTCQB: UEEC),manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it has been accepted as a Walmart.com and Jet.com supplier, and will offer three HemoStyp wound care products for online retail sale. HemoStrip® Hemostatic Bandages, BooBoo Strip Hemostatic Bandages, and a multipack of HemoStyp® Trauma Gauze will be available for purchase on Walmart.com and Jet.com in the near future. 

About United Health Products Inc. 
United Health Products Inc. (UHP) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose. HemoStyp is an all natural product designed to absorb exudate/drainage from wounds to help control bleeding. UHP is focused on identifying new markets and applications for its products and expanding its current markets. UHP currently sells a suite of hemostatic products to the dental, veterinary and retail markets.
For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Company Contact:
United Health Products, Inc.
877-358-3444

IR Contact:
PAN Consultants Ltd.
Philippe Niemetz 
212-344-6464 

  


United Health Products Files IDE Pre-Submission with the FDA for Approval to Begin Human Trials of HemoStyp®

Henderson, Nevada – June 19, 2018 – United Health Products, Inc. (OTCQB: UEEC),manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that after successfully completing a series of animal tests, it has filed an IDE pre-submission application with the Food and Drug Administration (FDA) to begin human trials of HemoStyp. The filing was made in conjunction with a previously filed Class III PMA submission application for HemoStyp for general surgical use in abdominal, cardiovascular and thoracic procedures to control bleeding sites. 

An Investigational Device Exemption (IDE) allows an investigational device (i.e., a device that is the subject of a clinical study) to be used in order to collect safety and effectiveness data required to support a premarket approval (PMA).  All statistical power calculations have been completed, and procedural protocols have been vetted for this submission. UHP expects to confer imminently with the FDA to confirm receipt of the Protocol, and to begin testing upon approval.

About Premarket Approval (PMA): 
https://www.fda.gov

About United Health Products Inc. 
United Health Products Inc. (UHP) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose. HemoStyp is an all natural product designed to absorb exudate/drainage from wounds to help control bleeding. UHP is focused on identifying new markets and applications for its products and expanding its current markets. UHP currently sells a suite of hemostatic products to the dental, veterinary and retail markets.
For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Company Contact:
United Health Products, Inc.
877-358-3444

IR Contact:
PAN Consultants Ltd.
Philippe Niemetz 
212-344-6464

United Health Products Forms Medical Advisory Board

Henderson, Nevada – March 19, 2018 – United Health Products, Inc. (OTCQB: UEEC),manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for the healthcare and wound care sectors, is pleased to announce the formation of a Medical Advisory Board.  Joining this newly formed Board are: 

Gerard Abate, MD Former Executive Director, Medical Affairs for Fortune 500 company Quest Diagnostics, where he directed 80+ Medical Affairs group that includes 8 clinical franchise medical directors, (oncology, genetics, women’s health, cardiovascular-metabolism, neurology, infectious disease/inflammation),HEOR team, publications group, MSLs, genetic counselors and project management.

Joseph M. Chalil, MD Senior Medical Director, Medical Affairs, North America, DBV Technologies SA, Montrouge France and New York NY, a clinical-stage bio-pharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin®.

Michael Erik Jessen, MD Professor and Chairman, and Frank M. Ryburn, Jr. Distinguished Chair in Cardiothoracic Surgery and Transplantation, Department of Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center.

Richard Massoth, DDS, MSD received his specialty training in Endodontics and his Masters of Science in Dentistry from Boston University in 1982. He has been an Adjunct Professor at the UCLA School of Dentistry and has been in clinical practice for 36 years. Dr. Massoth has been a published author, a frequent symposium speaker, and a leader serving in various positions in organized dentistry.

David W. Ramey DVM Thirty-four years of clinical experience as a full-time practitioner: Written thirteen books on various aspects of equine health, five book chapters, and have had over seventy papers published in professional journals. Frequent speaker: Invited podium speaker, lecturing on various topics in universities, conventions, and continuing education seminars around the United States, as well as Canada, Australia, and the UK.

Zachariah P. Zachariah, MD Medical Director, UHealth Cardiology Fort Lauderdale. Clinical Faculty, Department of Cardiology, University of Miami. Board member Florida Board of Governors. Member Board of Trustees, Chairman, Technology  Transfer  Committee Member- Executive Committee. Member, Academic Affairs & Strategic Planning Committee, Nova Southeastern University.

As the company continues to pursue its application to have HemoStyp approved for clinical use in the United States and South Korea, it looks forward to calling upon these experts in the fields of medicine, veterinary medicine and dental medicine to pursue various opportunities in these different markets. Douglas K. Beplate, CEO, UHP, said,” We are extremely pleased to have such highly regarded thought leaders join and work with us to help advance the company to the next stage of development.”  Visit the company’s website for the complete bios of the Medical Advisory Board.

Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Company Contact:
United Health Products, Inc.
877-358-3444

IR Contact:
PAN Consultants Ltd.
Philippe Niemetz 
212-344-6464 



United Health Products Expands Animal Testing for HemoStyp® in Support of PMA Application, Human Trials to Follow

Henderson, Nevada – March 13,2018 – United Health Products, Inc. (OTCQB: UEEC),manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it is launching expanded and more robust animal testing for HemoStyp within the next two weeks. These tests are expected to take approximately two to three weeks to complete, following which the protocols for human pilot trials will be confirmed. The human pilot trials are expected to commence within three weeks of animal testing completion.  Both the expanded animal testing and human trials are being conducted to support the company's HemoStyp PMA submission for internal surgical use and are being done in coordination with the FDA. 
"After consulting with the FDA regarding our PMA application for HemoStyp, we will conduct expanded animal testing, following which our human pilot trial protocol will be confirmed," said Douglas K. Beplate, CEO, UHP.  "We expect to complete both the expanded animal testing and human pilot trials within the next 14 weeks, following which we will present our findings to the FDA." 

About Premarket Approval (PMA): 
https://www.fda.gov

About United Health Products Inc. 
United Health Products Inc. (UHP) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose. HemoStyp is an all natural product designed to absorb exudate/drainage from wounds to help control bleeding. UHP is focused on identifying new markets and applications for its products and expanding its current markets. UHP currently sells a suite of hemostatic products to the dental, veterinary and retail markets.
For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Company Contact:
United Health Products, Inc.
877-358-3444

IR Contact:
PAN Consultants Ltd.
Philippe Niemetz 
212-344-6464 

 

United Health Products Receives CE Mark Approval for HemoStyp® Product Now Approved for Use in European Economic Area

Henderson, Nevada – March 13,2018 – United Health Products, Inc. (OTCQB: UEEC), manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it has obtained Class III and CE mark approval for HemoStyp in the European Economic Area (EEA). The EEA comprises the 28 European Union members and a number of other countries.  Accordingly, HemoStyp is approved for use in internal surgical procedures in more than 30 countries.

“We are pleased to have received CE mark approval for HemoStyp, as this allows us to consider partnership and marketing proposals for the European market,” said Douglas K. Beplate, CEO, UHP.

The approval was received following the provision of all required documentation by the relevant regulatory agencies. The CE marking– CE is an acronym for the French term "Conformité Européenne"– certifies that a product has met EEA health, safety, and environmental requirements, which ensure consumer safety. Manufacturers in the EEA and abroad must meet CE marking requirements where applicable to market their products in Europe. A manufacturer who has gone through the conformity assessment process may affix the CE mark to its product. With the CE marking, the product may be marketed throughout the EEA, which comprises 33 countries with a population of exceeding 517 million and a GDP exceeding $17 trillion. For a list of countries that require the CE marking, see: CE Marking Countries.

About United Health Products Inc. 
United Health Products Inc. (UHP) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose. HemoStyp is an all natural product designed to absorb exudate/drainage from wounds to help control bleeding. UHP is focused on identifying new markets and applications for its products and expanding its current markets. UHP currently sells a suite of hemostatic products to the dental, veterinary and retail markets.
For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Company Contact:
United Health Products, Inc.
877-358-3444

IR Contact:
PAN Consultants Ltd.
Philippe Niemetz 
212-344-6464

United Health Products Announces Completion of FDA PMA for HemoStyp®

Henderson, Nevada – February 5, 2018  United Health Products, Inc. (OTCQB: UEEC) ) today announced that, following its January 17 face-to- face meeting with FDA experts and officials, it has completed and submitted all materials relevant for the premarket approval (PMA) for HemoStyp. The PMA program is designed to confirm the safety of the HemoStyp product for use in internal human procedures. UHP has submitted additional inspection and registration forms to the CtQ Pilot program for final approval and confirmation. The PMA submission is for the approval of Class III indication and internal surgical use of Hemostyp.

The CtQ program is a sub-program of the PMA umbrella specific to facility and production safety. The estimated sales for internal surgical markets for hemostatic products (global hemostatic agents market) in 2017 are expected to be more than $7 billion. HemoStyp belongs to a subset of these markets whose 2017 sales are estimated at approximately $2.8 Billion, and are expected to nearly double to approximately $5.5 Billion by 2022. Overall, the global hemostatic agents market is estimated to grow at 7.1% annually, to reach $8.3 billion by 2022. http://industryarc.com/Report/15189/hemostats-market.html).

About United Health Products Inc. 
United Health Products Inc. (UHP) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose. HemoStyp is an all natural product designed to absorb exudate/drainage from wounds to help control bleeding. UHP is focused on identifying new markets and applications for its products and expanding its current markets. UHP currently sells a suite of hemostatic products to the dental, veterinary and retail markets.
For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Company Contact:
United Health Products, Inc.
877-358-3444

IR Contact:
PAN Consultants Ltd.
Philippe Niemetz 
212-344-6464

United Health Products Issues FDA Update

Henderson, Nevada – January 22, 2018 – United Health Products, Inc. (OTCQB: UEEC) manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that, following a face-to-face meeting between FDA and key UHP representatives, it will pursue its PMA class III filing under the FDA's CtQ Pilot program for use in internal surgical procedures. Further, the company has decided to withdraw from its class II extension of use application with the FDA. It was determined that the PMA application allows a much broader range of indication than the prior 510K class II of expanded usage.proval for use in the Australian market within 30 days. 

About United Health Products Inc. 
United Health Products Inc. (UHP) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose. HemoStyp is an all natural product designed to absorb exudate/drainage from wounds to help control bleeding. UHP is focused on identifying new markets and applications for its products and expanding its current markets. UHP currently sells a suite of hemostatic products to the dental, veterinary and retail markets.
For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Company Contact:
United Health Products, Inc.
877-358-3444

IR Contact:
PAN Consultants Ltd.
Philippe Niemetz 
212-344-6464 

  


United Health Products Applying for Class III Designation for HemoStyp® by Australian TGA

Henderson, Nevada – December 12, 2017 – United Health Products, Inc. (OTCQB: UEEC) United Health Products, Inc. (UHP) (OTC: UEEC), manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for the healthcare and wound care sectors, today announced it is applying to have HemoStyp designated as a Class III medical device with Australia’s Therapeutics Goods Administration (TGA, counterpart to the U.S. FDA).  Similar to the US FDA Class III application, this will allow for internal surgical use. The company’s Australian TGA consultants believe that UHP has the requisite test data and documentation to obtain rapid approval in Australia, and that HemoStyp® could obtain approval for use in the Australian market within 30 days. 

About TGA 
The Therapeutic Goods Administration (TGA) is Australia's regulatory authority for therapeutic goods. We carry out a range of assessment and monitoring activities to ensure therapeutic goods available in Australia are of an acceptable standard with the aim of ensuring that the Australian community has access, within a reasonable time, to therapeutic advances. https://www.tga.gov.au/about-tga

About United Health Products Inc. 
United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

For further information contact Investor Relations:
Philippe Niemetz
PAN Consultants Ltd.
212-344-6464
p.niemetz@panconsultants.com



FDA Selects HemoStyp® for CtQ Pilot Program

Henderson, Nevada – December 04, 2017 – United Health Products, Inc. (OTCQB: UEEC) manufacturer and marketer of HemoStyp®,  a patented hemostatic gauze for the healthcare and wound care sectors, today announced that it is proceeding with its application for HemoStyp under the  FDA’s new and innovative CtQ Pilot Program. The FDA selected UHP’s HemoStyp as only one of nine participants for the program. UHP management has scheduled its first face-to-face meeting with FDA experts for January 17, 2018 to provide the agency with whatever information it needs to advance the application for premarket approval (PMA).

The FDA has stated that it intends to work collaboratively with pilot program participants during the review of their PMA submission to define characteristics of the device that are critical to product quality, and how these characteristics are controlled in design and manufacturing prior to the post market inspection. For pilot program participants, the FDA would forego conducting the standard PMA preapproval inspection, and a post market inspection focusing on the PMA applicant’s implementation of the critical to quality characteristics would be conducted instead.

The CtQ Pilot Program was created to identify products that have a chemical makeup of demonstrated safe interaction with the body –as evidenced by years of prior product usage and studies-- to be approved for Class III internal surgical use. The program’s intent is to allow products that have demonstrated repeated safe interaction to enter the market in a more efficient manner.  This application will run simultaneously with the company’s prior Class II application for expanded indication. The market for 2017 internal surgical market for hemostatic products is estimated at in excess of seven billion dollars, and is expected to grow at 7.1% over the next few years, to reach more than $8.3 billion by 2022. (http://industryarc.com/Report/15189/hemostats-market.html

Concurrent with its CtQ Pilot Program participation, UHP reaffirms that its current Class II application  – Expanded Indication submission with the US FDA-- continues to progress, and is in an advanced stage of review 

About Premarket Approval Application Critical to Quality (PMA CtQ) Pilot Program 
Top-quality medical devices help the FDA better protect and promote public health. And one of the top priorities for FDA’s medical devices center is a focus on quality.

More specifically, the FDA is working with stakeholders—industry, health care providers, patients, payers, and investors—to build a strong Case for Quality.

This program allows the FDA to identify device manufacturers that consistently produce high-quality devices. By doing so, we can better focus our resources helping other manufacturers raise their level of quality. This program also helps the FDA identify and promote practices that support consistent quality manufacturing, and align our regulatory, enforcement, compliance approaches with those practices.

The FDA launched the Case for Quality in 2011 following an in-depth review of device quality data and feedback from both FDA and industry stakeholders. The FDA's analysis flagged certain widespread or common manufacturing risks that impact product quality. The review also showed manufacturers that focus on and manage those risks often become more productive, receiving fewer complaints, needing to open fewer CAPAs and investigations, and having lower quality-related product costs than their competitors. In simple terms, the review identified that an investment in quality has long-term payoffs.

About United Health Products Inc. 
United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

For further information contact Investor Relations:
Philippe Niemetz
PAN Consultants Ltd.
212-344-6464
p.niemetz@panconsultants.com



United Health Products Announces Hemostyp® as a featured product of Dick’s Sporting Goods Advanced Wound Care Kit.

Henderson, Nevada – November 09, 2017 – United Health Products, Inc. (OTCQB: UEEC) announced that their 2’ x 4” Trauma Gauze™ product has been selected as the feature component for a new Advanced Wound Care Kit for Dick’s Sporting Goods (NYSE DKS). With today’s environment when the unexpected can happen anywhere, both in the wild and in urban areas, having an advanced trauma kit can be the difference between survival and tragedy. The Hemostyp® pouches will be included under the Field and Stream label. They will be available in their stores nationwide beginning in Feb 2018 and will be displayed in various locations throughout the stores.

About Dick’s Sporting Goods

Dick's Sporting Goods, Inc., sometimes shortened toDick's, is a Fortune 500 Americansporting goodsretailingcorporation headquartered inCoraopolis, PennsylvaniainGreater Pittsburgh. Dick's has 610 stores in 47 states (no stores inAlaska,Hawaii, andMontanaas of mid-March 2016) primarily in theEastern United States. The company also owns Golf Galaxy, Inc., a golf specialty retailer, with 82 stores in 30 states. The company also operates specialty chains True Runner andField & Stream. Founded in 1948 by Richard "Dick" Stack, the chain has expanded to become one of the largest sporting goods retailers in the world. www.dickssportinggoods.com.

About United Health Products Inc. 
United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

For further information contact Investor Relations:
Philippe Niemetz
PAN Consultants Ltd.
212-344-6464
p.niemetz@panconsultants.com

 

United Health Products Issues FDA Submission Update

Henderson, Nevada – October 10, 2017 – United Health Products, Inc. (OTCQB: UEEC) a manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that its current Expanded Indication Submission Class II application for HemoStyp for internal usage with the U.S. FDA continues to progress, and is in an advanced stage of review.  In addition, the company is pleased to announce that it has applied to the FDA’s new and innovative CtQ Pilot Program premarket approval PMA (Class III internal usage) for HemoStyp.
The CtQ Pilot Program was created to identify products that have a chemical makeup of demonstrated safe interaction with the body –as evidenced by years of prior product usage and studies—to be approved for Class III internal surgical use. The program’s intent is to allow products that have demonstrated repeated safe interaction to enter the market in a more efficient manner.  This application will run simultaneously with the company’s prior Class II application for expanded indication. The market for 2017 for internal surgical hemostatic products is estimated to be more than seven billion, and is expected to grow at 7.1% over the next few years, to reach more than $8.3 billion by 2022.
(http://industryarc.com/Report/15189/hemostats-market.html)  

About United Health Products Inc. 
United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

For further information contact Investor Relations:
Philippe Niemetz
PAN Consultants Ltd.
212-344-6464
p.niemetz@panconsultants.com

 

United Health Products and Patterson/Animal Health International Launch Nationwide Marketing Campaign for HemoStyp® Products to U.S. Veterinary Healthcare Market

Henderson, Nevada – August 28, 2017 – United Health Products, Inc. (OTCQB: UEEC) a manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that, in conjunction with Patterson Veterinary/Animal Health International, Inc. (AHI), a subsidiary of Patterson Companies, Inc., it will conduct a marketing campaign to more than 8,000 companion animal clinics in the United States. 

Patterson Veterinary/AHI, United Health Products’ exclusive distributor to the U.S. animal health market, with a sales force more than 400 strong, will officially launch the campaign on September 1, which will last until year end 2017.  The campaign’s objective is to significantly increase sales of four HemoStyp products to the $10 Billion domestic veterinary healthcare market, and to attain  major market share gains in that market, one of the five that United Health Products serves.

 "We expect the marketing campaign with Patterson Veterinary/AHI to lead to significant sales in the third and fourth quarter of this year,” said Douglas K. Beplate, CEO. “Patterson Veterinary/AHI is one of the largest animal health companies in the United States, and we have been working diligently with them to make this program a success. Additional incentives to customers, coupled with our already leading cost effective pricing, should enable us to expand our footprint in this rapidly growing market. “ 

About Patterson Veterinary/Animal Health International
Patterson Veterinary/Animal Health International, Inc. is the premier animal health company in North America and has been serving the needs of customers for more than 40 years. No other distributor has a broader product offering. Patterson Veterinary/Animal Health International represents over 1,000 manufacturers that supply products focused on companion animal, equine, beef and dairy cattle, poultry, and swine. Patterson Veterinary/Animal Health International offers products ranging from vaccines and pharmaceuticals to state of the art equipment and software. Patterson Companies acquired Animal Health International in May of 2016 to become one of the largest Veterinary suppliers in the country.

About United Health Products Inc. 
United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

For further information contact Investor Relations:
Philippe Niemetz
212-344-6464 ● PAN Consultants Ltd. 
p.niemetz@panconsultants.com 



United Health Products Inc. To File Late 2016 Audited Year End

Henderson, NV -  April 18, 2017 - United Health Products, Inc. (OTCQB: UEEC) announced that revenues for the fourth quarter of 2016 were approximately $252,000 and that the company is expecting to see increasing quarterly revenues for 2017. The company’s independent registered public accountants, Pritchett Siler & Hardy, P.C., are in the process of auditing 2016 financial statements and will present to the prior auditors RRBB for their opinion and approval. A late filing of our Form 10-K for the fiscal year ended December 31, 2016 is anticipated within the next two weeks. Douglas Beplate, CEO of UHP, commented that this is a major step forward for the company to have an auditing firm recognized in the auditing of public posted companies performing the audits as we move forward in creating market awareness and value.

About United Health Products Inc.

United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Contact:

United Health Products, Inc.
877-358-3444



United Health Products Inc. To Host Dial in Corporate Update

Henderson, NV -  March 31, 2017 - United Health Products, Inc. (OTCQB: UEEC) will hold a dial in conference for shareholders, potential shareholders and those seeking to learn more about the company on Tuesday, April 4, 2017 at 12:30 PM Eastern Time. Douglas Beplate CEO and Louis Schiliro Director of Manufacturing will discuss present business, marketing plans for 2017, and future events for 2017. To listen to the discussion:

Participant Instructions: 

1.  Call your Dial-In Number: (712) 451-0011 
2.  Enter your Access Code: 291859.

Anyone not able to access or attend the call can go to the company’s website www.unitedhealthproductsinc.com and listen to the entire call which will posted as an audio file on Wednesday, April 5, by noon EST.

About United Health Products Inc.

United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Contact:

United Health Products, Inc.
877-358-3444

 


United Health Products Inc. To Host Dial in Corporate Update

Henderson, NV -  March 31, 2017 - United Health Products, Inc. (OTCQB: UEEC) will hold a dial in conference for shareholders, potential shareholders and those seeking to learn more about the company on Tuesday, April 4, 2017 at 12:30 PM Eastern Time. Douglas Beplate CEO and Louis Schiliro Director of Manufacturing will discuss present business, marketing plans for 2017, and future events for 2017. To listen to the discussion:

Participant Instructions: 

1.  Call your Dial-In Number: (712) 451-0011 
2.  Enter your Access Code: 291859.

Anyone not able to access or attend the call can go to the company’s website www.unitedhealthproductsinc.com and listen to the entire call which will posted as an audio file on Wednesday, April 5, by noon EST.

About United Health Products Inc.

United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Contact:

United Health Products, Inc.
877-358-3444

 


United Health Products Inc. To Host Dial in Corporate Update

Henderson, NV -  January 12, 2017 - United Health Products, Inc. (OTCQB: UEEC) will hold a dial-in conference for shareholders, potential shareholders and those seeking to learn more about the company on Tuesday January 17, 2017 at 12:30 PM Eastern Time. Douglas Beplate CEO and Louis Schiliro Director of Manufacturing will discuss year end 2016, present business and current rollout to the veterinary market, marketing plans for 2017 and future events for 2017. To listen to the discussion:

Participant Instructions: 

1.  Call your Dial-In Number: (712) 451-0011 
2.  Enter your Access Code: 291859.

Anyone not able to access or attend the call can go to the company’s website www.unitedhealthproductsinc.com and listen to the entire call which will posted as an audio file on Wednesday, January 18 by noon EST.

About United Health Products Inc.

United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Contact:

United Health Products, Inc.
877-358-3444